非小细胞肺癌罕见驱动基因突变及靶向药物的研究进展  

Research Progress of Rare Driver Gene Mutations and Targeted Drugs in Non-small Cell Lung Cancer

作　　者：胡琳 王晓华 HU Lin;WANG Xiaohua(Graduate School of Bengbu Medical College,Bengbu 233030,China;Department of Respiratory and Critical Medicine,Changzhou Second People′s Hospital Affiliated to Nanjing Medical University,Changzhou 213000,China)

机构地区：[1]蚌埠医学院研究生院,安徽蚌埠233030 [2]南京医科大学附属常州第二人民医院呼吸与危重症医学科,江苏常州213000

出　　处：《医学综述》2023年第9期1752-1759,共8页Medical Recapitulate

摘　　要：非小细胞肺癌(NSCLC)不是一个单一的疾病实体,而是一组不同分子驱动的肿瘤。分子检测已成为NSCLC管理不可或缺的组成部分。鉴于表皮生长因子受体突变的NSCLC靶向治疗所带来的显著临床反应率和靶向药物的不断研发,精准化、个体化治疗的观点更加深入人心,但罕见基因突变的研究进展较缓慢,临床诊疗难度较大,患者预后相对较差。识别这些致癌驱动基因,如人表皮生长因子受体2、鼠类肉瘤病毒癌基因、转染重排,并尽可能将患者分类到评估新型靶向治疗方法的临床试验中,不仅可以促进药物的临床试验,还可以延长患者的生存时间、提高患者的生活质量。Non-small cell lung cancer(NSCLC)is not a single disease entity,but a group of different molecularly driven tumors.Molecular detection has become an integral part of NSCLC management.In view of the significant clinical response rate brought about by the NSCLC targeted therapy for epidermal growth factor receptor mutations and the continuous research and development of targeted drugs,the viewpoint of precision and individualized treatment is more deeply rooted in the hearts of the people,but the research progress of rare gene mutations is slower,the clinical diagnosis and treatment is more difficult,and the prognosis is relatively poor.Identifying these oncogenic driver genes,such as human epidermal growth factor receptor 2,kirsten rat sarcoma viral oncogene and rearranged during transfection,and classifying patients as far as possible into clinical trials evaluating novel targeted therapies,can not only facilitate the clinical trials of the drugs,but also extend the survival and improve quality of life of the patients.

关 键 词：非小细胞肺癌 基因突变 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]